Boehringer Deal Leads EU Watchdog To Close Probe

Law360, New York (July 6, 2011, 1:51 PM EDT) -- The European Commission closed its probe Wednesday into claims that Boehringer Ingelheim GmbH abused the patent system to corner the multibillion-dollar market for emphysema and related lung disease treatments after the German drugmaker settled with rival Almirall SA.

The four-year-old investigation stemmed from Almirall's complaint that in a bid to block its would-be competitor, Boehringer misled the European regulators in order to patent new treatments for chronic obstructive pulmonary disease based in part on a new active ingredient discovered by Barcelona-based Almirall.

At the urging of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.